12 completed, 1 terminated. 13 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Completed 12, Terminated 1 |
| Phase 2 | 1 | Completed 1 |
Follow prexasertib: new trials by email Literature Review of prexasertib trials Research Report on prexasertib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma Prexasertib, Irinotecan - Desmoplastic Small Round Cell Tumor, Rhabdomyosarcoma | Phase 1 / Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 21 | 2019-09-17 | 2025-02-20 |
| Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors Prexasertib, Cyclophosphamide, Gemcitabine - Brain Tumor, Brain Tumor, Recurrent | Phase 1 | Completed | St. Jude Children's Research Hospital | 21 | 2019-08-08 | 2025-02-07 |
| Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial Prexasertib, Mitoxantrone, Etoposide - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 1 | Terminated | Dana-Farber Cancer Institute | 2 | 2019-01-18 | 2019-06-12 |
| A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors LY3300054, Prexasertib - Cancer | Phase 1 | Completed | Dana-Farber Cancer Institute | 17 | 2018-05-16 | 2021-04-15 |
| Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors Prexasertib, Olaparib - Solid Tumor | Phase 1 | Completed | Geoffrey Shapiro, MD, PhD | 29 | 2017-03-10 | 2021-09-02 |
| Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors Laboratory Biomarker Analysis, Pharmacokinetic (PK) study, Prexasertib - Childhood Solid Neoplasm, Recurrent Malignant Solid Neoplasm | Phase 1 | Completed | Children's Oncology Group | 30 | 2017-02-27 | 2023-12-20 |
| A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer [¹⁴C]Prexasertib, Prexasertib - Advanced Cancer | Phase 1 | Completed | Eli Lilly and Company | 6 | 2016-09-22 | 2019-08-01 |
| A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer prexasertib, ralimetinib - Advanced Cancer, Metastatic Cancer | Phase 1 | Completed | Eli Lilly and Company | 9 | 2016-08-10 | 2018-12-14 |
| Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Cytarabine, Fludarabine Phosphate, Laboratory Biomarker Analysis - Chronic Myelomonocytic Leukemia, Recurrent Acute Myeloid Leukemia | Phase 1 | Completed | M.D. Anderson Cancer Center | 15 | 2016-05-04 | 2023-10-04 |
| A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer Prexasertib, Cisplatin, Cetuximab - Head and Neck Neoplasms | Phase 1 | Completed | Eli Lilly and Company | 70 | 2016-02-24 | 2019-02-15 |
| A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers Prexasertib - Neoplasm | Phase 1 | Completed | Eli Lilly and Company | 12 | 2015-10-01 | 2017-05-22 |
| A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer Prexasertib, Cisplatin, Cetuximab - Neoplasm Metastasis, Colorectal Neoplasms | Phase 1 | Completed | Eli Lilly and Company | 167 | 2014-06-18 | 2020-04-01 |
| A Phase 1 Study in Participants With Advanced Cancer Prexasertib - Advanced Cancer, Squamous Cell Carcinoma | Phase 1 | Completed | Eli Lilly and Company | 150 | 2010-02-01 | 2016-05-10 |
Neoplasms (4) · Neoplasm Metastasis (3) · Carcinoma, Non-Small-Cell Lung (2) · Central Nervous System Neoplasms (2) · Colorectal Neoplasms (2) · Leukemia, Myeloid, Acute (2) · Anus Neoplasms (1) · Brain Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Squamous Cell (1) · Desmoplastic Small Round Cell Tumor (1) · Head and Neck Neoplasms (1) · Leukemia, Myelomonocytic, Chronic (1) · Medulloblastoma (1) · Microphthalmia, Isolated, with Coloboma 5 (1)
Eli Lilly and Company (6) · Dana-Farber Cancer Institute (2) · Children's Oncology Group (1) · Geoffrey Shapiro, MD, PhD (1) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · St. Jude Children's Research Hospital (1)
United States (11) · France (1) · Germany (1) · Japan (1) · United Kingdom (1)
Cynthia J Wetmore (1) · Emily Slotkin, MD (1) · Eric S Winer, MD (1) · Gautam Borthakur (1) · Geoffrey Shapiro, MD (1) · Geoffrey T Shapiro, MD (1) · Giles W. Robinson, MD (1)
PMID 27044938, PMID 28138028, PMID 29643063, PMID 32371584, PMID 33495309, PMID 33745032, PMID 33881209, PMID 34559360, PMID 34904813
2015 (3), UM1CA097452 (1)